[{"id":"8581491d-374e-47d8-8cf7-20ff1d417401","acronym":"","url":"https://clinicaltrials.gov/study/NCT02017457","created_at":"2021-01-18T09:13:52.590Z","updated_at":"2025-02-25T14:34:27.169Z","phase":"Phase 2","brief_title":"Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.","source_id_and_acronym":"NCT02017457","lead_sponsor":"Carlos Graux, MD, PhD","biomarkers":" NPM1 • WT1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" MLL-PTD","tags":["NPM1 • WT1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL-PTD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • hydroxyurea"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2019-12-10"}]